Krystal Biotech (KRYS) Expected to Release Quarterly Earnings on Monday

Krystal Biotech (NASDAQ:KRYS) is expected to issue its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect the company to post earnings of $1.79 per share and revenue of $125.77 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, August 3rd. The company reported $1.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.70 by $0.09. The business had revenue of $119.22 million for the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. On average, analysts expect Krystal Biotech to post $7.33 EPS for the current fiscal year and $8.78 EPS for the next fiscal year.

Krystal Biotech Stock Up 2.4%

Shares of NASDAQ KRYS opened at $332.29 on Friday. The stock’s fifty day simple moving average is $337.46 and its 200 day simple moving average is $308.68. The stock has a market capitalization of $9.84 billion, a price-to-earnings ratio of 41.64 and a beta of 0.50. Krystal Biotech has a 52-week low of $184.02 and a 52-week high of $382.54.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. The trade was a 1.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino A. Rossi sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 13.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KRYS has been the subject of a number of recent analyst reports. Zacks Research lowered Krystal Biotech from a “hold” rating to a “strong sell” rating in a research report on Friday, October 23rd. William Blair raised Krystal Biotech to a “strong-buy” rating in a research note on Wednesday, September 23rd. Jefferies Financial Group restated a “buy” rating and set a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Chardan Capital upgraded Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Finally, Weiss Ratings raised shares of Krystal Biotech from a “buy (b-)” rating to a “buy (b)” rating in a research note on Friday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $377.20.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.